Insomnia drug class may not influence death and exacerbation risks among patients with COPD
Session: C98, Risky Business: Predicting Consequences of OSA
Date and Time: 2:51 p.m. ET, Tuesday, May 23, 2023
Location: Marriott Marquis Washington, Independence Ballroom, Salons E-H (Level M4)
ATS 2023, Washington, DC – Chronic obstructive pulmonary disease patients newly prescribed non-benzodiazepine benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo and other brands), a class of hypnotic drugs prescribed for insomnia, did not have an increased risk of exacerbations requiring hospitalizations or of death than those prescribed ...








